Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 300-203-7 | CAS number: 93924-11-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restrictions because the study appears to adhere to the principles outlined in OECD 420 and was GLP compliant.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13.
Cross-reference
- Reason / purpose for cross-reference:
- read-across: supporting information
Reference
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restrictions because the study appears to adhere to the principles outlined in OECD 420 and was GLP compliant.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- yes
- Remarks:
- This study was assessed using OECD 420 rather than 401 since OECD 401 is no longer supported by OECD.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Neodene 6
- Substance type: C6 alpha olefin
- Physical state: Liquid - Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Industries, Indianapolis, Indiana
- Weight at study initiation: Weights recorded on day 0
- Fasting period before study: Yes
- Housing: Individually caged
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.0 to 25.0
- Humidity (%): 36 to 71%
- Photoperiod (hrs dark / hrs light): 12 dark/12 light
IN-LIFE DATES: From: 1981-06-30 To: 1981-07-30 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Specific amount of test material administered calculated using fasted body weights on day 0 and specific gravity of 0.673 for Neodene 6.
- Doses:
- 0, 1000, 1800, 3200, and 5600 mg/kg Neodene 6, 10 ml/kg deionised water (control)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days (or other?) 14 days
- Frequency of observations and weighing: Observations for clinical signs of toxicity were made hourly for six-hours post-dosing, at 24 hours and twice daily until study termination on day 14. Body weights were determined on days -1, 0, 7, and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: Clinical signs, body weight - Statistics:
- Statistical analysis of body weights included calculation of the mean and standard error. Determination of the significance of body weight changes on days 7 and 14 compared to controls was made using an independent T-test. A probability level of 0.05 was used as criterion for significance. No information reported on method used to calculate LD50.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 600 mg/kg bw
- Mortality:
- No deaths were reported in this study.
- Clinical signs:
- other: Mucoid diarrhoea was observed over the first day in treated rats. Other clinical effects observed included polyuria, hyperactivity, hypoactivity, chewing movements, hypersensitivity to touch, red eye discharge, soft stool, and diarrhea. Many of the effe
- Gross pathology:
- The only remarkable change observed during necropsy was bilateral luminal dilation with clear fluid in the uterus which did not occur in the controls, but occurred in 4/5 of 1000 mg/kg treated females, 1/5 of 3200 mg/kg treated females, and 4/5 of 5600 mg/kg treated females. The pathologist noted that this was a common occurrence and it was not considered treatment-related.
- Other findings:
- One female rat treated with 1800 mg/kg Neodene 6 had dyspnoea on days 11 to 14 and a red nasal discharge on day 13. A partial occlusion of the trachea and bronchi was found at necropsy. These findings were not considered treatment-related.
- Interpretation of results:
- other:
- Remarks:
- Not classified because LD50 is greater than the requirements for a Category 4 toxicant (2000 mg/kg) Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 for Neodene 6 was reported to be > 5600 mg/kg in the rat.
- Executive summary:
In an acute oral toxicity study, groups of fasted Fisher 344 rats (5 male, 5 female) were given a single oral dose via gavage of Neodene 6 at doses of 0, 1000, 1800, 3200, or 5600 g/kg bw and observed for 14 days. Controls received deionised water.
No deaths occurred during this study and body weight was not affected by treatment. Clinical signs of toxicity included mucoid diarrhoea over the first day in treated rats. Although there were other clinical signs noted, they also occurred in the controls and were sporadic and therefore not related to treatment. The only remarkable change observed during necropsy was bilateral luminal dilation with clear fluid in the uterus of some treated females rats. This change, which was not observed in control animals, occurred in 4/5 of 1000 mg/kg treated females, 1/5 of 3200 mg/kg treated females, and 4/5 of 5600 mg/kg treated females. The pathologist noted that this was a common occurrence and it was not considered treatment-related. The acute oral LD50 for Neodene 6 alpha olefin in male and female rats was reported as >5600 mg/kg.
This study received a Klimisch score of 1 and is classified as reliable with restriction because it was conducted in accordance with OECD 420 and was GLP compliant.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 982
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- yes
- Remarks:
- This study was assessed using OECD 420 rather than 401 since OECD 401 is no longer supported by OECD.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Hex-1-ene
- EC Number:
- 209-753-1
- EC Name:
- Hex-1-ene
- Cas Number:
- 592-41-6
- Molecular formula:
- C6H12
- IUPAC Name:
- hex-1-ene
- Details on test material:
- - Name of test material (as cited in study report): Neodene 6
- Substance type: C6 alpha olefin
- Physical state: Liquid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Neodene 6
- Substance type: C6 alpha olefin
- Physical state: Liquid
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Industries, Indianapolis, Indiana
- Weight at study initiation: Weights recorded on day 0
- Fasting period before study: Yes
- Housing: Individually caged
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.0 to 25.0
- Humidity (%): 36 to 71%
- Photoperiod (hrs dark / hrs light): 12 dark/12 light
IN-LIFE DATES: From: 1981-06-30 To: 1981-07-30
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Specific amount of test material administered calculated using fasted body weights on day 0 and specific gravity of 0.673 for Neodene 6.
- Doses:
- 0, 1000, 1800, 3200, and 5600 mg/kg Neodene 6, 10 ml/kg deionised water (control)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days (or other?) 14 days
- Frequency of observations and weighing: Observations for clinical signs of toxicity were made hourly for six-hours post-dosing, at 24 hours and twice daily until study termination on day 14. Body weights were determined on days -1, 0, 7, and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: Clinical signs, body weight - Statistics:
- Statistical analysis of body weights included calculation of the mean and standard error. Determination of the significance of body weight changes on days 7 and 14 compared to controls was made using an independent T-test. A probability level of 0.05 was used as criterion for significance. No information reported on method used to calculate LD50.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 600 mg/kg bw
- Mortality:
- No deaths were reported in this study.
- Clinical signs:
- other: Mucoid diarrhoea was observed over the first day in treated rats. Other clinical effects observed included polyuria, hyperactivity, hypoactivity, chewing movements, hypersensitivity to touch, red eye discharge, soft stool, and diarrhea. Many of the effe
- Gross pathology:
- The only remarkable change observed during necropsy was bilateral luminal dilation with clear fluid in the uterus which did not occur in the controls, but occurred in 4/5 of 1000 mg/kg treated females, 1/5 of 3200 mg/kg treated females, and 4/5 of 5600 mg/kg treated females. The pathologist noted that this was a common occurrence and it was not considered treatment-related.
- Other findings:
- One female rat treated with 1800 mg/kg Neodene 6 had dyspnoea on days 11 to 14 and a red nasal discharge on day 13. A partial occlusion of the trachea and bronchi was found at necropsy. These findings were not considered treatment-related.
Applicant's summary and conclusion
- Interpretation of results:
- other:
- Remarks:
- Not classified because LD50 is greater than the requirements for a Category 4 toxicant (2000 mg/kg) Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 for Neodene 6 was reported to be > 5600 mg/kg in the rat.
- Executive summary:
In an acute oral toxicity study, groups of fasted Fisher 344 rats (5 male, 5 female) were given a single oral dose via gavage of Neodene 6 at doses of 0, 1000, 1800, 3200, or 5600 g/kg bw and observed for 14 days. Controls received deionised water.
No deaths occurred during this study and body weight was not affected by treatment. Clinical signs of toxicity included mucoid diarrhoea over the first day in treated rats. Although there were other clinical signs noted, they also occurred in the controls and were sporadic and therefore not related to treatment. The only remarkable change observed during necropsy was bilateral luminal dilation with clear fluid in the uterus of some treated females rats. This change, which was not observed in control animals, occurred in 4/5 of 1000 mg/kg treated females, 1/5 of 3200 mg/kg treated females, and 4/5 of 5600 mg/kg treated females. The pathologist noted that this was a common occurrence and it was not considered treatment-related. The acute oral LD50 for Neodene 6 alpha olefin in male and female rats was reported as >5600 mg/kg.
This study received a Klimisch score of 1 and is classified as reliable with restriction because it was conducted in accordance with OECD 420 and was GLP compliant.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)